Ma Yingjie, Wang Jing, Li Qin, Cao Bangwei
Department of Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, P.R. China.
Nutr Cancer. 2021;73(2):196-205. doi: 10.1080/01635581.2020.1743873. Epub 2020 Mar 30.
Triple-negative breast cancer (TNBC) comprises about 10-20% of all diagnosed breast cancers. Increasing evidence shows that the omega-3 polyunsaturated fatty acids (ω-3PUFAs), docosahexaenoic acid and eicosapentaenoic acid, can influence the development, progression, and prognosis of TNBC In Vivo and In Vitro; however, clinical evidence supporting the effect of ω-3PUFAs on TNBC is lacking. Research has demonstrated that ω-3PUFAs can induce apoptosis in breast cancer cells by inhibiting the PI3K/AKT signal transduction pathway, and that ω-3PUFAs can improve the effectiveness of chemotherapy drugs. Using ω-3PUFA supplementation in addition to pharmacotherapy in the treatment of breast cancer may result in enhanced anti-tumor effects that will be particularly applicable to difficult to treat phenotypes such as TNBC. The aim of the current review was to summarize the evidence-base supporting the antitumor effects of omega-3 PUFAs in TNBC.
三阴性乳腺癌（TNBC）约占所有确诊乳腺癌的10%-20%。越来越多的证据表明，ω-3多不饱和脂肪酸（ω-3PUFAs），即二十二碳六烯酸和二十碳五烯酸，在体内和体外均可影响TNBC的发生、发展及预后；然而，支持ω-3PUFAs对TNBC作用的临床证据尚缺乏。研究表明，ω-3PUFAs可通过抑制PI3K/AKT信号转导通路诱导乳腺癌细胞凋亡，且ω-3PUFAs可提高化疗药物的疗效。在乳腺癌治疗中，除药物治疗外补充ω-3PUFAs可能会增强抗肿瘤效果，这将特别适用于TNBC等难以治疗的表型。本综述的目的是总结支持ω-3PUFAs对TNBC抗肿瘤作用的证据基础。
